Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
暂无分享,去创建一个
C. Bachert | N. Krug | J. Hohlfeld | N. Zhang | S. Korn | H. Renz | R. Buhl | T. Werfel | A. Kirsten | O. Kornmann | K. Beeh | H. Garn | W. Timmer | S. Ignatenko | Ursula Homburg | A. Turowska | D. Kappeler | J. Zeitvogel | J. Bille | Cordelia Rogon | J. Renz
[1] D. Cockcroft,et al. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.
[2] L. Boulet,et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.
[3] R. Dahl,et al. Marked epithelial cell pathology and leukocyte paucity in persistently symptomatic severe asthma. , 2013, American journal of respiratory and critical care medicine.
[4] L. Boulet,et al. Inhaled allergen bronchoprovocation tests. , 2013, The Journal of allergy and clinical immunology.
[5] J. Kuhlmann,et al. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. , 2013, Toxicology and applied pharmacology.
[6] Bart Hilvering,et al. Clinical utility of asthma biomarkers: from bench to bedside , 2013, Biologics : targets & therapy.
[7] K. Bracke,et al. Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.
[8] S. Wenzel,et al. Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.
[9] Jason Z. Deng,et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER) , 2013, The Lancet.
[10] T. Hansen,et al. Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure. , 2013, Pulmonary pharmacology & therapeutics.
[11] N. Krug,et al. Low-dose endotoxin inhalation in healthy volunteers - a challenge model for early clinical drug development , 2013, BMC Pulmonary Medicine.
[12] B. O'connor,et al. The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[13] Hergen Spits,et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. , 2012, Immunity.
[14] Monica Kraft,et al. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. , 2012, The Journal of allergy and clinical immunology.
[15] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[16] S. Holgate. Trials and tribulations in identifying new biologic treatments for asthma. , 2012, Trends in immunology.
[17] S. Wenzel. Severe asthma: from characteristics to phenotypes to endotypes , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[18] S. Holgate. Innate and adaptive immune responses in asthma , 2012, Nature Medicine.
[19] S. Wenzel. Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.
[20] I. Pali-Schöll,et al. Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes. , 2012, Nucleic acid therapeutics.
[21] Nicola A Hanania,et al. Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.
[22] Prescott G Woodruff,et al. Human asthma phenotypes: from the clinic, to cytokines, and back again , 2011, Immunological reviews.
[23] A. Chang,et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils) , 2010, Thorax.
[24] Sally E Wenzel,et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.
[25] Parameswaran Nair,et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.
[26] P. O'Byrne. Allergen-induced airway inflammation and its therapeutic intervention , 2009, Allergy, asthma & immunology research.
[27] Barmak Modrek,et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.
[28] Ana Sousa,et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.
[29] W. Henke,et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. , 2008, The Journal of allergy and clinical immunology.
[30] P. J. Barnes,et al. Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.
[31] S. Wenzel,et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.
[32] S. Winandy,et al. No DL1 Notch ligand? GATA be a mast cell , 2007, Nature Immunology.
[33] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[34] D. Postma,et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. , 2005, The Journal of allergy and clinical immunology.
[35] G. Scheuch,et al. Peripheral deposition of α1‐protease inhibitor using commercial inhalation devices , 2003, European Respiratory Journal.
[36] L. Khachigian,et al. Centenary Nobel Prize in Physiology or Medicine for the cell cycle , 2001, Journal of Molecular Medicine.
[37] A. Ray,et al. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. , 1999, The Journal of clinical investigation.
[38] P. O'Byrne,et al. Repeatability of allergen-induced airway inflammation. , 1999, The Journal of allergy and clinical immunology.
[39] Y. Yamaguchi,et al. GATA‐3 represses gp91phox gene expression in eosinophil‐committed HL‐60‐C15 cells , 1998, FEBS letters.
[40] H. Boushey,et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.
[41] D. Cockcroft,et al. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. , 1987, The Journal of allergy and clinical immunology.
[42] J. Hankinson,et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. , 2000, American journal of respiratory and critical care medicine.